Platicis 50mg Inj.
MRP: ₹316.20
Packaging
50Ml INJECTION
Composition
Cisplatin 50mg
Company
Zydus Cadila
MRP: ₹316.20
Packaging
50Ml INJECTION
Composition
Cisplatin 50mg
Company
Zydus Cadila
| Medicine | Company | Price | You Save |
|---|---|---|---|
| Platinex-50mg Inj. | Khandelwal | ₹275.00 | Save ₹41.20 |
| Platikem-50mg Inj. | Alkem Labs | ₹288.00 | Save ₹28.20 |
| Cisteen-50mg Inj. | Miracauls | ₹310.00 | Save ₹6.20 |
| Oncoplatin-AQ-50mg Inj. | Sun Pharma | ₹328.00 | — |
| Cytoplatin 50 mg Injection | Cipla | ₹349.00 | — |
| Blastolem-50mg Inj. | Elder Pharma | ₹370.00 | — |
| Uniplatin 50mg Inj. | United Biotech | ₹522.00 | — |
Severe nausea and vomiting. Serious toxic effects on the kidneys, bone marrows and ears. Hypomagnesaemia, hypocalcaemia, hyperuricaemia. Peripheral neuropathies, papilloedema, optic neuritis, seizures. Ototoxicity (children) manifested as tinnitus, loss of hearing, deafness or vestibular toxicity. Potentially Fatal: Rarely, renal damage due to inadequate hydration during therapy. Very rarely life-threatening myelosuppression. Anaphylactoid reactions (rare) and cardiac abnormalities.
Synergistic with 5-fluorouracil and etoposide. Efficacy increased and toxicity reduced when combined with radioprotecting agent WR 2721. At doses ≤100 mg, cisplatin is an ideal drug to combine with other cytotoxic drugs; unlike other antineoplastic drugs, it causes little myelosuppression. Potentially Fatal: Potentiates nephrotoxicity with aminoglycosides. Increased toxicity when combined with other cytotoxic drugs.
Patients with severe renal or auditory disorder, known hypersensitivity, severe bone marrow suppression, peripheral neuropathy, pregnancy, lactation.
Cisplatin modifies cell cycle by interfering with DNA structure and function. Effects are most prominent during the S phase but cells are killed at all stages. Cisplatin synergises with other anticancer drugs e.g. fluorouracil. It has a narrow therapeutic margin and is highly toxic. Absorption: Well absorbed (intraperitoneal). Distribution: Concentrated in the liver, kidneys, large and small intestines; poor penetration into the CNS. Excretion: Urine. Elimination half-life: 25-49 min (initial), 58-73 hr (terminal).
Patients with renal or hepatic disorder, myelosuppression. Monitor renal, neurological and auditory function. Perform blood counts regularly. Maintain adequate hydration before and 24 hr after admin to minimise nephrotoxicity.
Take orally with food and water, as directed by your physician.
Keep in a cool, dry place away from sunlight and moisture.
This content is for educational purposes only. Please consult your doctor before use.
| Brand Name | Form | Price |
|---|---|---|
| Akostol 100 mg Tablet 10s | TAB | ₹79.00 |
| Aldonil 50mg Tab | TAB | ₹58.00 |
| Alupent Syrup 100ml | SYRUP | ₹75.00 |
| Alupent-10mg Tab | TAB | ₹48.00 |
| Amlodac 5mg Tablet 15s | TAB | ₹0.00 |
| Arnx 50mg Tablet 10s | TAB | ₹199.00 |
| Atorva TG Tablet 10s | TAB | ₹0.00 |
| Atorva-E Tab 10s | TAB | ₹0.00 |
| Avanext 200 Tablet 4s | TAB | ₹733.00 |
| Azildac 40mg Tablet 10s | TAB | ₹72.50 |
| Benspar Cap | CAP | ₹45.00 |
| Betanase-5mg Tab | TAB | ₹4.00 |
| Bilypsa 4mg Tablet 45s | TAB | ₹1,397.00 |
| Bql-10mg Tab | TAB | ₹28.00 |
| Bql-2.5mg Tab | TAB | ₹15.00 |
Written by: SastiMedic Medical Team
Reviewed by: Registered Pharmacist